跳至主要内容
临床试验/NCT04968548
NCT04968548进行中(未招募)不适用

Determination and Validation of Lung EpiCheck®: A Multianalyte Assay for Lung Cancer Prediction. A Case-Control Study

Nucleix Ltd.31 个研究点 分布在 2 个国家目标入组 5,000 人开始时间: 2021年9月17日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
Nucleix Ltd.
入组人数
5,000
试验地点
31
主要终点
Collection of blood samples

研究概览

简要总结

This study is part of the development and validation of a non-invasive lung screening test which aim to identify early stage lung cancer in patients at high risk for lung cancer.

详细描述

This is a prospective, case-control, multi-center, observational nonsignificant risk study. The study aims to collect blood and clinical data from subjects undergoing Low Dose CT (LDCT) for lung cancer screening and subjects with confirmed lung cancer.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
50 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Collection of blood samples

时间窗: 24 Months

Collect blood to support the development and validation of a multi analyte test for lung cancer screening

Clinical data collection

时间窗: 24 Months

Collect clinical data to support the development and validation of a multi analyte test for lung cancer screening

次要结局

  • Specificity(36 Months)
  • Negative Predictive Value(36 Months)
  • Performance(36 Months)
  • Sensitivity(36 Months)
  • Positive Predictive Value(36 Months)

研究者

发起方
Nucleix Ltd.
申办方类型
Industry
责任方
Sponsor

研究点 (31)

Loading locations...

相似试验

Determination and Validation of a Multi-analyte... | 临床试验